Medication info
Coibest Tablet 150/12.5 mg

Coibest Tablet 150/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Irbesartan›150mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Ahn-Guk Pharmaceutical Co., Ltd.
Appearance
Pink, oval, biconvex, film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200805819 · Notified 2008.05.26 · Insurance code 650202990

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
This drug is administered once daily, regardless of meals. Dose titration of each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this drug may be administered concomitantly with other antihypertensive agents. 2. When using this drug as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into account baseline blood pressure, target blood pressure, and the expected increase in the likelihood of achieving the treatment goal compared with monotherapy. Treatment is usually initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks up to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Initial treatment with this drug is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because this drug contains hydrochlorothiazide, it is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dosage adjustment is necessary in patients with renal impairment and a creatinine clearance of 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this drug. ○ Patients with hepatic impairment This drug should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dosage adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dosage adjustment is necessary in older adults.
Child dose
Children and adolescents under 18 years of age: The safety and efficacy of this drug have not been established.

Ingredients

Manufacturer
Ahn-Guk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
  • moderate hypertension
  • severe hypertension
View approved original text

This medication is used to lower blood pressure in patients with essential hypertension. It is also used in initial therapy to reach target blood pressure for patients with moderate to severe hypertension (stage 2) who do not achieve sufficient blood pressure control with monotherapy or those who need to take two or more medications together. In other words, it is effective for patients who have difficulty controlling their blood pressure and helps maintain stable blood pressure management.

How to take

Adult dose

This drug is administered once daily, regardless of meals. Dose titration of each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this drug may be administered concomitantly with other antihypertensive agents. 2. When using this drug as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into account baseline blood pressure, target blood pressure, and the expected increase in the likelihood of achieving the treatment goal compared with monotherapy. Treatment is usually initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks up to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Initial treatment with this drug is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because this drug contains hydrochlorothiazide, it is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dosage adjustment is necessary in patients with renal impairment and a creatinine clearance of 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this drug. ○ Patients with hepatic impairment This drug should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dosage adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dosage adjustment is necessary in older adults.

Child dose

Children and adolescents under 18 years of age: The safety and efficacy of this drug have not been established.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, and should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in pregnant or potentially pregnant women, nursing mothers, patients with anuria, patients with severe renal impairment, patients with certain electrolyte abnormalities or liver disease, and patients with a history of hereditary angioedema. Patients with specific disorders such as hypotension, impaired renal function, liver disease, heart valve disease, and closed-angle glaucoma should use this medication cautiously, as there may be an increased risk of skin cancer; therefore, sun exposure should be limited, and skin condition should be checked regularly. During the use of this medication, side effects such as dizziness, fatigue, nausea, vomiting, and abnormal urination may occur, so if symptoms are severe or persistent, consult a physician. Dizziness or fatigue may occur while driving or operating machinery, so caution is needed, and patients at risk of hypotension should manage sodium intake and fluid status appropriately. Regular blood tests should confirm renal function and electrolyte levels, paying particular attention to changes in potassium levels. Diabetic patients may be affected in blood glucose control, so consult a physician before and after taking the medication, and inform if there are any other medications being taken that may interact with this medication. This medication is not recommended for use during pregnancy or breastfeeding, and in pediatric and adolescent populations. In case of an overdose, symptoms such as hypotension, electrolyte imbalance, nausea, and drowsiness may occur; contact a medical institution immediately for appropriate measures. This medication should be stored out of the reach of children and kept sealed in its original container.

Side effects

  • Dizziness
  • fatigue
  • nausea
  • vomiting
  • abnormal urination
  • elevated BUN
  • increased creatine kinase
  • elevated creatinine
  • orthostatic dizziness
  • headache
Show 81 more
  • fainting
  • low blood pressure
  • tachycardia
  • edema
  • flushing
  • cough
  • diarrhea
  • dyspepsia
  • altered taste
  • jaundice
  • hepatitis
  • abnormal liver function
  • sexual dysfunction
  • changes in libido
  • kidney function impairment
  • limb edema
  • arthralgia
  • myalgia
  • tinnitus
  • angioedema
  • rash
  • urticaria
  • hyperkalemia
  • decreased serum potassium
  • decreased serum sodium
  • low blood pressure
  • shingles
  • colon cancer
  • hematoma
  • anaphylactic shock
  • anaphylactic reaction
  • intestinal vascular edema
  • anemia
  • thrombocytopenia
  • hypoglycemia
  • depression
  • sleep disorders
  • orthostatic hypotension
  • arrhythmia
  • aplastic anemia
  • bone marrow suppression
  • neutropenia
  • agranulocytosis
  • hemolytic anemia
  • leukopenia
  • thrombocytopenia
  • shortness of breath
  • pancreatitis
  • loss of appetite
  • constipation
  • gastric irritation
  • sialadenitis
  • appetite loss
  • interstitial nephritis
  • renal impairment
  • transient blurred vision
  • yellow vision
  • weakness
  • muscle spasms
  • toxic epidermal necrolysis
  • necrotizing vasculitis
  • skin erythematous lupus-like reaction
  • skin erythematous lupus reactivation
  • photosensitivity reaction
  • fever
  • electrolyte imbalance
  • hyperuricemia
  • diabetes
  • hyperglycemia
  • increased cholesterol
  • elevated triglycerides
  • hypokalemia
  • hyponatremia
  • hypochloremic alkalosis
  • muscle cramps
  • drowsiness
  • restlessness
  • myalgia
  • convulsions
  • frequent urination
  • dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from exposure to air or moisture. It is important to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, oval, biconvex, film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.